Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease

Anas Zaher; Hassan Elsaygh

doi:10.5114/pg.2025.151891

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2025
vol. 20

Send email

Copy url:

abstract:

Review paper

Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease

Anas Zaher

¹

,

Hassan Elsaygh

²

New York Presbyterian Brooklyn Methodist Hospital, New york, US
Department of Medicine, University of Debrecen, Debrecen, Hungary

Gastroenterology Rev 2025; 20 (2): 115–120

DOI: https://doi.org/10.5114/pg.2025.151891

Online publish date: 2025/06/06

View full text Get citation

PlumX metrics:

The global epidemic of obesity has led to a surge in metabolic-associated steatotic liver disease (MASLD), which poses a significant global health burden. Current therapeutic strategies primarily focus on lifestyle modifications, weight loss interventions, and the use of pharmacological agents such as glucagon-like peptide-1 receptor agonists (GLP-1RAs). Recently, the FDA approved resmetirom, a selective thyroid hormone receptor- agonist. Both GLP-1RAs and resmetirom have individually demonstrated promising results in managing MASLD and associated metabolic disorders. However, the potential synergistic effects of combining these agents remain unexplored. This paper discusses the rationale for exploring the combination therapy of resmetirom and GLP-1RAs for managing MASLD.

keywords:

cirrhosis, hepatology, metabolic dysfunction-associated steatohepatitis, metabolic-associated steatotic liver disease, glucagon-like peptide-1 receptor agonists

Exploring synergistic therapy for metabolic dysfunction-associated steatotic liver disease

Anas Zaher 1 , Hassan Elsaygh 2

cirrhosis, hepatology, metabolic dysfunction-associated steatohepatitis, metabolic-associated steatotic liver disease, glucagon-like peptide-1 receptor agonists

Anas Zaher

¹

,

Hassan Elsaygh

²